Menu
← Oncology Approval Tracker
FDA DECISION ·
Hernexeos
zongertinib · Boehringer Ingelheim Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with unresectable or metastatic nonsquamous NSCLC and a HER2 (ERBB2) activating tyrosine kinase domain mutation by an FDA-approved test after prior systemic therapy.
LAMPGEN ANALYSIS
Why it matters
An oral HER2 kinase inhibitor became available for this molecular subgroup after systemic therapy.
What research teams should watch
Require the molecular report to identify the activating kinase-domain variant, since HER2 amplification or staining alone does not establish eligibility.
PRIMARY RECORDS